Pope KosalaraksaKulkanya ChokephaibulkitSuwat BenjaponpitakChitsanu PancharoenSunate ChuenkitmongkolSiham B'ChirXavier Da CostaEmmanuel VidorSanofi Pasteur SAKing Chulalongkorn Memorial Hospital, Faculty of Medicine Chulalongkorn UniversitySrinagarind hospitalFaculty of Medicine, Ramathibodi Hospital, Mahidol UniversityFaculty of Medicine, Siriraj Hospital, Mahidol UniversitySanofi PasteurSanofi Pasteur2019-08-232019-08-232018-05-04Human Vaccines and Immunotherapeutics. Vol.14, No.5 (2018), 1257-12652164554X216455152-s2.0-85042214406https://repository.li.mahidol.ac.th/handle/20.500.14594/46017© 2018 The Author(s). Published with license by Taylor & Francis © 2018, © Pope Kosalaraksa, Kulkanya Chokephaibulkit, Suwat Benjaponpitak, Chitsanu Pancharoen, Sunate Chuenkitmongkol, Siham B'Chir, Xavier Da Costa, and Emmanuel Vidor. Objective: To evaluate the long-term persistence of anti-hepatitis B surface (HBs) antibodies and the response to a HB challenge re-vaccination in children who had received a primary series of DTaP-IPV-HB-PRP∼T (Hexaxim™) or DTaP-IPV-HB/PRP∼T (Infanrix hexa™). Methods: Two cohorts of participants who had previously received HB vaccine at birth followed by either DTaP-IPV-HB-PRP∼T or DTaP-IPV-HB/PRP∼T co-administered with PCV7 at 2, 4, 6 months of age in a randomized, Phase III, observer-blind study in Thailand, were followed up for anti-HBs antibodies (geometric mean concentrations [GMCs] and seroprotection [SP] rate [% of participants with a titer ≥10 mIU/mL]) at 12–18 months of age and 9–10 years of age. A monovalent HB challenge re-vaccination was administered at 9–10 years of age and the anamnestic response was evaluated. Results: Anti-HBs GMCs and SP rates in the DTaP-IPV-HB-PRP∼T and DTaP-IPV-HB/PRP∼T groups were high and similar post-primary vaccination series (2477 mIU/mL and 99.5% and 2442 mIU/mL and 99.5%, respectively) and declined to a similar extent in each group at 12–18 months (154.5 mIU/mL and 90.8% and 162.3 mIU/mL and 96.5%, respectively). Antibody levels further declined at 9–10 years of age (13.3 mIU/mL and 49.3% and 8.0 mIU/mL and 42.9%) and a strong anamnestic response occurred in each group post-HB challenge re-vaccination (92.8% and 98.7%, respectively). Conclusion: The kinetics of long-term anti-HBs antibody persistence were similar following a primary series of DTaP-IPV-HB-PRP∼T or DTaP-IPV-HB/PRP∼T. The response to a subsequent HB challenge re-vaccination was strong and similar in each group, demonstrating persisting immune memory.Mahidol UniversityImmunology and MicrobiologyMedicinePharmacology, Toxicology and PharmaceuticsArticleSCOPUS10.1080/21645515.2018.1426418